Articles

Research News

Published on 17 October 2017

HIV patients will accept generic treatments

Human immunodeficiency virus (HIV) patients in high-income countries are likely to accept the introduction of generic antiretroviral (ARV) drugs, according to a study carried out by researchers in Ireland [1]....

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2017.0604.041

3.468 views

Read more →

Readers' Comments

Published on 14 December 2015

Pro-generics policies and the backlog in medicines registration in South Africa: implications for access to essential and affordable medicines Comment by Ernest Schay, Bayer Thank you for this very interesting...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2015.0404.044

3.466 views

Read more →

Published on 29 January 2015

2014/4 GaBI Journal Table of Contents

Contents Editor’s Letter Fourth and final issue of GaBI Journal’s third volume Editorial Availability and procurement of generics in hospitals among medium-sized European countries Letters to the Editor Access to...

3.443 views

Read more →

Published on 22 October 2014

2013/1 GaBI Journal Table of Contents

Contents Editor's Letter Editor’s introduction to the wide range of topics in the initial issue of the second volume of GaBI Journal Letters to the Editor The ethics of biosimilars...

3.383 views

Read more →

Published on 22 October 2014

2014/1 GaBI Journal Table of Contents

Contents Editor's Letter Editor’s introduction to the initial issue of the third volume of GaBI Journal Editorial Drug shortages hit US oncologists hard Letters to the Editor Common or distinct...

3.379 views

Read more →

Editor's Letter

Published on 29 September 2021

Latest features in GaBI Journal, 2021, Issue 3

This issue of GaBI Journal contains articles dealing with some very practical issues related to the evaluation, describing, and use of generic and biosimilar products. These issues include the uncertainty...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2021.1003.012

3.377 views

Read more →

Commentary

Published on 19 July 2022

Substitution and interchangeability: time for a conversation?

Author byline as per print journal: Chad Rieger1, MBA; Lisa Hall1, PhD; David Lim2,3, DPH Abstract: Bandiera et al. (2002) identified the potential for competitors’ promotional materials to use certain...

Australia, interchangeability, substitution

DOI: 10.5639/gabij.2022.1102.009

3.368 views

Read more →

Editor's Letter

Published on 11 December 2015

Fourth and final issue of GaBI Journal’s fourth volume

This last issue of 2015 starts with a Commentary by Drs Christoph Baumgärtel and Brian Godman concerning the approval of generic versions of narrow therapeutic margin products; including immunosuppressant drugs....

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2015.0404.034

3.350 views

Read more →

Research News

Published on 27 September 2017

Healthcare professionals will accept generic HIV treatments

Healthcare professionals working with HIV patients in high-income countries are likely to accept the introduction of generic antiretroviral drugs (ARVs), according to a study carried out by researchers in Ireland...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2017.0603.029

3.335 views

Read more →

Published on 04 November 2014

2014/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2014, Issue 3 Editorial Regional regulatory processes for the approval of biosimilars; differences and similarities Original Research Barriers to market uptake of...

3.335 views

Read more →

Research News

Published on 27 February 2020

Poor traceability of biologicals in UK ADR reporting indicates the need for improvements to ensure patient safety

Submitted: 27 January 2020; Revised: 29 January 2020; Accepted: 29 January 2020; Published online first: 25 February 2020 Biological medical products (biologicals) are derived from living cells or organisms. Due to...

Author(s): Kevin Klein, PhD

DOI: 10.5639/gabij.2020.0902.012

3.313 views

Read more →